rituximab biosimilar / Coherus Oncology - LARVOL DELTA

Highly sensitive in vitro cytokine release assay incorporating high-density preculture. (PubMed, J Immunotoxicol) - "Here, PBMC were exposed to panitumumab, trastuzumab, rituximab, or alemtuzumab at 0.1, 0.3, 1, and 3 μg/well for 24 or 48 hr under both non-HDC and HDC conditions. Anti-CD3 mAb and anti-CD28 SA mAb also induced significant release of cytokines under HDC conditions compared with that under non-HDC conditions. In conclusion, CRA incorporating HDC into the air-drying solid-phase method using human PBMC could sensitively capture the FR-dependent cytokine release potential of mAb."

Journal • Preclinical • Inflammation

Clinicopathological study of HBV-DNA negative hepatitis B-related cryoglobulinemia-related glomerulonephritis (JSN 2020) - "Treated with steroids and immunosuppressive drugs such as rituximab, Cryofiltration, and 2 cases were in remission, 1 case was dialysis induction. 2017).It is possible that Cryo is produced by the presence of a trace amount of virus even in the case of DNA negative. The effectiveness of combination therapy of drugs, steroids, and immunosuppressants is suggested, and it is important to accumulate future cases."

Clinical • Complement-mediated Rare Disorders • Glomerulonephritis • Hepatitis B • Hepatitis C Virus • Hepatology • Infectious Disease • Lupus Nephritis • Nephrology • Renal Disease